|Bid||6.06 x 2000|
|Ask||6.07 x 2000|
|Day's Range||5.90 - 6.09|
|52 Week Range||4.45 - 7.88|
|PE Ratio (TTM)||-4.39|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.
BOSTON, June 28, 2017-- ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on new immunotherapies, today announced the initiation of enrollment in the stereotactic arm of its Phase 1 multicenter ...
NEW YORK, NY / ACCESSWIRE / June 21, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process ...